Notes

Advances in the treatment of transthyretin heart amyloidosis: Present as well as emerging remedies.
Legislative change in recent years allows the prescription of medicinal cannabis for patients receiving palliative care. There appears to be widespread community support of its use in this context.

The aim of this article is to provide an overview of current research on the use ofmedicinal cannabis within the palliative care context for both children and adults.

The evidence needed to support the useof medicinal cannabis for symptom control is limited and still emerging. It is unlikely that medicinal cannabis will be used as a first-line agent for the management of pain, nausea and other specific symptoms, but it may have an adjuvant or complementary role in symptom management within palliative care. Consistent with the Therapeutic Goods Administration advice, these authors recommend that general practitioners encourage patients to participate in trials or programs that objectively monitor benefit and toxicity ofmedicinal cannabis.
The evidence needed to support the use of medicinal cannabis for symptom control is limited and still emerging. It is unlikely that medicinal cannabis will be used as a first-line agent for the management of pain, nausea and other specific symptoms, but it may have an adjuvant or complementary role in symptom management within palliative care. Consistent with the Therapeutic Goods Administration advice, these authors recommend that general practitioners encourage patients to participate in trials or programs that objectively monitor benefit and toxicity of medicinal cannabis.
There is a great deal of interest in thepotential symptomatic benefits ofmedicinal cannabis among parents ofchildren and adolescents with developmental disorders.

This article provides an overview of what is known about medicinal cannabis as a treatment for paediatric developmental disorders.

While there is emerging evidence in support of medicinal cannabis for some adult mental health disorders, to date the evidence in children and adolescents is scant. selleck kinase inhibitor Reports from uncontrolled observational studies suggest that cannabidiol-rich products may be helpful in reducing behavioural problems in autistic youth. Cannabidiol appears to have a relatively benign adverse effect profile and therefore may be worth considering as a treatment option in some cases. Several controlled clinical trials are underway that will provide more definitive information on the therapeutic value of medicinal cannabis in paediatric developmental and behavioural disorders.
While there is emerging evidence in support of medicinal cannabis for some adult mental health disorders, to date the evidence in children and adolescents is scant. Reports from uncontrolled observational studies suggest that cannabidiol-rich products may be helpful in reducing behavioural problems in autistic youth. Cannabidiol appears to have a relatively benign adverse effect profile and therefore may be worth considering as a treatment option in some cases. Several controlled clinical trials are underway that will provide more definitive information on the therapeutic value of medicinal cannabis in paediatric developmental and behavioural disorders.
Medicinal cannabis prescriptions are onthe rise in Australia, and general practitioners will increasingly encounter patients using cannabis-based products.

The aim of this review is to provide a primer on the safety issues that need tobe considered with medicinal cannabis.

Medicinal cannabis is generally well tolerated when dosed appropriately. Itisimportant for doctors to consider carefully the Δ9-tetrahydrocannabinol (THC) and/or cannabidiol (CBD) content of the products. CBD is not intoxicating and has fewer safety concerns than THC. When commencing a new medicinal cannabis product, the recommendation isto prescribe relatively low doses and slowly up-titrate the dose. This aims to minimise dose-related toxicities and the potential for drug-drug interactions with concomitant medications. THC found in medicinal cannabis may acutely impair cognitive function and is best not prescribed to children or adolescents unless the benefits outweigh the risks. THC-containing cannabis products should not be prescribed to individuals with angina or a history of myocardial infarction, or to those who have a personal or family history of psychosis.
Medicinal cannabis is generally well tolerated when dosed appropriately. It is important for doctors to consider carefully the Δ9-tetrahydrocannabinol (THC) and/or cannabidiol (CBD) content of the products. CBD is not intoxicating and has fewer safety concerns than THC. When commencing a new medicinal cannabis product, the recommendation is to prescribe relatively low doses and slowly up-titrate the dose. This aims to minimise dose-related toxicities and the potential for drug-drug interactions with concomitant medications. THC found in medicinal cannabis may acutely impair cognitive function and is best not prescribed to children or adolescents unless the benefits outweigh the risks. THC-containing cannabis products should not be prescribed to individuals with angina or a history of myocardial infarction, or to those who have a personal or family history of psychosis.
Medical cannabis use is increasingly common in Australia. Patients and physicians need to be aware of the important implications that such use mayhave for driving.

The aim of this article is to briefly reviewthe scientific evidence regarding cannabis and driving impairment and discuss current legal issues affecting patients, as well as to update physicians on relevant issues and the best guidance to offer their patients.

Delta-9-tetrahydrocannabinol (THC) impairs driving performance and can increase crash risk. These effects are more pronounced in people who use THC occasionally and can last for up to eight hours with oral THC products. There is no evidence that cannabidiol (CBD) impairs driving. Patients using THC-containing products should avoid driving and other safety-sensitive tasks (eg operating machinery), particularly during initiation of treatment and in the hours immediately following each dose. Patients may test positive for THC even if they do not feel impaired, and medical cannabis use does not currently exempt patients from mobile (roadside) drug testing and associated legal sanctions.
My Website: https://www.selleckchem.com/products/R788(Fostamatinib-disodium).html